Biomarkers to Detect Endocrine Therapy Resistance
NCT: NCT06067503 · RECRUITING
Brief Summary
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.
Frequently Asked Questions
What is Biomarkers to Detect Endocrine Therapy Resistance?
Biomarkers to Detect Endocrine Therapy Resistance is a clinical trial registered under NCT06067503. Current status: RECRUITING.
What is the status of NCT06067503?
The current status of NCT06067503 (Biomarkers to Detect Endocrine Therapy Resistance) is: RECRUITING.
When did Biomarkers to Detect Endocrine Therapy Resistance start?
Biomarkers to Detect Endocrine Therapy Resistance started on 2024-04-30.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.